Pharmacokinetic analysis during intravaginal progesterone-releasing devices (PRID®/CIDR®) application in the mare

Pohl, Oliver; Buff, Samuel; Garnier, François; Guérin, Philippe J; Lefranc, A.-C.

doi:10.21836/pem20090202

Cited by 6 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings demonstrated that progesterone concentrations rapidly increase and decrease after insertion and removal of the IPRD device used herein. Previously, other authors have shown that CIDR, another type of IPRD, increased progesterone concentrations in plasma of mares [ 22 , 31 , 32 , 33 , 34 ]. Experiment 2, conducted in a large embryo transfer operation, demonstrated that the IPRD synchronization protocol used herein was equally effective in establishing satisfactory pregnancy rates in acyclic embryo recipient mares and did not result in greater pregnancy losses when compared to cyclic mares or those synchronized with LAP4.…”

Section: Discussionmentioning

confidence: 99%

Use of Intravaginal Progesterone-Releasing Device Results in Similar Pregnancy Rates and Losses to Long-Acting Progesterone to Synchronize Acyclic Embryo Recipient Mares

Segabinazzi

Andrade

Alvarenga

et al. 2021

Veterinary Sciences

View full text Add to dashboard Cite

The objectives of this study were: (1) to assess uterine features and serum progesterone concentrations of acyclic mares synchronized and resynchronized with intravaginal progesterone release device (IPRD), and (2) to compare pregnancy rates and losses of cyclic and acyclic embryo recipient mares treated with different synchronization protocols. In Experiment 1, mares (n = 12) received estradiol for 3 days (E2-3d), and then 24 h after the last injection, an IPRD was inserted and kept in place for 9 days. Three days after IPRD removal, mares were treated with E2-3d, and then a new IPRD was inserted and maintained for three days. Serum progesterone concentrations were assessed 2, 6, and 12 h after insertion and removal of IPRD, and then daily from the insertion of the first IPRD to one day after removal of the second IPRD. Experiment 2 was conducted with embryo recipient mares randomly assigned to four groups: (1) Cyclic: mares (n = 75) had ovulation confirmed after receiving a single dose of histrelin when a periovulatory follicle was first detected, (2) LAP4: acyclic mares (n = 92) were treated with E2-3d and then administered a single dose of LAP4 24 h after the last estradiol injection, (3) IPRD: acyclic mares (n = 130) were treated with E2-3d and an IPRD for 4–8 days, and (4) RE-IPRD: acyclic mares (n = 32) were synchronized as in the IPRD group but not used for embryo transfer (ET), then 8 to 15 days later, the mares were resynchronized with E2-3d and an IPRD for 4–8 days. In vivo-produced Day-8 embryos were collected and transferred 4–8 days after ovulation or progesterone treatments. Mares in IPRD and RE-IPRD groups had the intravaginal device removed immediately before ET, and then a new IPRD was inserted right after ET. Pregnancy diagnosis was performed at 5, 30, and 60 days after ET. Once pregnancy was confirmed, mares in the three acyclic groups received weekly injections of LAP4 (1.5 g) until 120 days of pregnancy. Mares in IPRD and RE-IPRD groups had the device removed three days after the first pregnancy diagnosis. In Experiment 1, progesterone concentrations increased rapidly starting 2 h after insertion of IPRD (p < 0.05); then, concentrations plateaued well above pregnancy maintenance until removal on days 9 and 3, respectively. Progesterone concentrations were reduced to baseline 24 h after IPRD removal (p < 0.05). For experiment 2, there was no difference in pregnancy rates across groups (65–74%) or pregnancy losses by 60 days of gestation (7–12%) (p > 0.05). In conclusion, the IPRD used herein resulted in a rapid increase and a sharp decline in progesterone concentrations upon its insertion and removal, respectively. Finally, our results demonstrated that IPRD could be a compatible alternative to LAP4 to synchronize and resynchronize acyclic embryo recipient mares.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of Intravaginal Progesterone-Releasing Device Results in Similar Pregnancy Rates and Losses to Long-Acting Progesterone to Synchronize Acyclic Embryo Recipient Mares

Segabinazzi

Andrade

Alvarenga

et al. 2021

Veterinary Sciences

View full text Add to dashboard Cite

show abstract

“…Os protocolos padrões que mimetizam a fase diestral da égua tem como base a progesterona na apresentação injetável por via intramuscular de longa ação (LA), no entanto apresentam alto custo e são passíveis de formação de abcesso quando não administrados de maneira correta (POHL et al, 2009;NEGRETTI et al, 2018). Outro ponto negativo é o aumento elevado dos níveis séricos de progesterona permanecendo em média 12 dias circulante, dificultando a reutilização desta receptora num curto período de tempo (VANDERWALL et al, 2007).…”

Section: Sincronização Receptoras Acíclicasunclassified

“…Além da via intravaginal ser uma alternativa conveniente de administração de progesterona em éguas, evitando o tratamento diário e/ou injeções, a maior vantagem é permitir o reuso da receptora, quando não há sucesso na inovulação, num período de tempo menor quando comparado a receptoras preparadas com progesterona injetável de longa ação (RIGOLETO JÚNIOR et al, 2021;SEGABINAZZI et al, 2021). Pohl et al (2009) demonstraram que após a inserção de um PRID® ou CIDR® (dispositivos intravaginais de liberação de P4 de bovinos) em éguas acíclicas, a concentração sérica de progesterona atingiu níveis de 17,8 e 19,9 nmol/L, respectivamente (5,59 a 6,25 ng/mL) em apenas nove horas e manteve um platô por oito dias. Rigoleto Júnior et al (2021) usando dispositivo com apenas 1g de progesterona em éguas acíclicas, observaram que a concentração sérica de progesterona (4,09 ng/mL) se elevou para níveis semelhantes aos demonstrados com os dispositivos usados por Pohl et al (2009) ou com progesterona injetável de longa ação.…”

Section: Referênciasunclassified

“…Pohl et al (2009) demonstraram que após a inserção de um PRID® ou CIDR® (dispositivos intravaginais de liberação de P4 de bovinos) em éguas acíclicas, a concentração sérica de progesterona atingiu níveis de 17,8 e 19,9 nmol/L, respectivamente (5,59 a 6,25 ng/mL) em apenas nove horas e manteve um platô por oito dias. Rigoleto Júnior et al (2021) usando dispositivo com apenas 1g de progesterona em éguas acíclicas, observaram que a concentração sérica de progesterona (4,09 ng/mL) se elevou para níveis semelhantes aos demonstrados com os dispositivos usados por Pohl et al (2009) ou com progesterona injetável de longa ação.…”

Section: Referênciasunclassified

See 1 more Smart Citation

Transferência de Embriões em Equinos: Receptoras Acíclicas

Flores,

Rodrigues,

Rigoleto Júnior

et al. 2023

Ensaios Ciênc.

View full text Add to dashboard Cite

Em equinos a principal biotécnica reprodutiva utilizada visando maior produtividade de potros por égua/ano é a Transferência de Embriões (TE) que permite manter a égua doadora da genética em suas atividades, enquanto outra geste seu potro. Para tanto é necessário preparar receptoras, ou seja, éguas comuns que irão gestar o embrião de uma égua pura de alto valor genético e ao utilizar protocolos hormonais é possível preparar o útero das receptoras dentro e fora da estação reprodutiva para que esteja apto à inovulação. Portanto, objetiva-se revisar a literatura sobre transferência de embriões em equinos com enfoque na preparação de receptoras. Os protocolos padrões, que mimetizam a fase diestral da égua, tem como base a progesterona (P4) na apresentação injetável por via intramuscular de longa ação (LA), no entanto, apresentam alto custo e são passíveis de formação de abcessos no local da aplicação quando não administradas de maneira correta, além disso a P4 permanece elevada na corrente sanguínea inviabilizando a reutilização desta receptora num curto período de tempo, caso a gestação não seja efetivada. Recentemente uma nova estratégia de hormonioterapia está sendo utilizada a campo, com dispositivos intravaginais a base de P4 utilizados em bovinos, os quais induzem rápida queda na P4 após sua retirada e sem os inconvenientes da aplicação injetável. Palavras-chave: Blastocisto. Dispositivo Intravaginal de Progesterona. Égua. Inovulação. Protocolo Hormonal. Abstract In equines, the main reproductive biotechnique used focused on greater productivity of foals per mare/year is called Embryo Transfer (ET) which allows to keep the genetic donor mare in her activities, while another animal gestates her foal. Therefore, it is necessary to prepare recipients, common mares that will gestate the embryo of high genetic value, by using hormonal protocols to prepare its uterus inside and outside the breeding season to get ready for inovulation. Therefore, the aim of this literature review is to study embryo transfer in horses with a focus on the preparation of recipients. The standard protocols, which mimic the mare's diesstral phase, are based on progesterone (P4) in the long-acting (LA) intramuscular injection, however, these protocols are expensive and susceptible to abscesses formation at the injection site when it is not administered correctly. In addition, P4 remains at high value in the bloodstream, preventing to reuse this receptor in a short period of time, if pregnancy is not successful. Recently, a new hormone therapy strategy is being used with P4-based intravaginal devices used in cattle, which induce a rapid drop in P4 after removing the device, without the inconvenience of injection. Keywords: Blastocyst. Inovulation. Mare. Hormonal Protocol. Progesterone Intravaginal Device.

show abstract

“…A variety of progesterone‐releasing intravaginal devices have been used in clinical broodmare practice (Foglia and others 1999, Newcombe 2002, Grimmett and others 2002, Handler and others 2006, Pohl and others 2009, Polasek and others 2017, Crabtree and others 2018). Interestingly, vaginal devices may, by their physical presence alone, cause mares to have a significant FSH response and induce oestrus (Thompson and others 1984).…”

Section: Pharmacological Stimulation Of Cyclicitymentioning

confidence: 99%

Update on the management of anoestrus and transitional phase in horses

Crabtree¹

2021

In Practice

View full text Add to dashboard Cite

Background: Practitioners are regularly presented with mares in anoestrus or the transitional phase of the reproductive cycle. The first aim for the practitioner is to determine what stage of the cycle the mare is likely in and then determine the likely timescale to spontaneous cyclic activity. If it is desirable for the mare to be bred sooner than this, management and/or pharmacological strategies can be implemented in an attempt to advance cyclic activity.Aim of the article: This article aims to update the practitioner with regard to the current and future methods of management and pharmacological therapies available to stimulate cyclic activity in the mare in anoestrus or transitional phase of the reproductive cycle.

show abstract

Pharmacokinetic analysis during intravaginal progesterone-releasing devices (PRID®/CIDR®) application in the mare

Cited by 6 publications

References 12 publications

Use of Intravaginal Progesterone-Releasing Device Results in Similar Pregnancy Rates and Losses to Long-Acting Progesterone to Synchronize Acyclic Embryo Recipient Mares

Use of Intravaginal Progesterone-Releasing Device Results in Similar Pregnancy Rates and Losses to Long-Acting Progesterone to Synchronize Acyclic Embryo Recipient Mares

Transferência de Embriões em Equinos: Receptoras Acíclicas

Update on the management of anoestrus and transitional phase in horses

Contact Info

Product

Resources

About